Abstract
Objectives: The nucleotide-binding domain leucine-rich repeat and pyrin domain containing receptor protein 3 (NLRP3) inflammasome is over activated in neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS), leading to chronic inflammation by activating several cytokines. A novel small-molecule inhibitor C77 was described to block NLRP3 inflammasome, therefore our study is focused in optimizing and understanding the capabilities of the small-molecule inhibitor for possible treatment of ALS. We hypothesize that C77 can cross the BBB and the muscle, therefore blocking NLRP3 inflammasome and slow disease progression and mortality.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
